- NCIt
- C171265
Loading cancer entity…
Loading cancer entity…
Clinical trials
11 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06369610 | Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment of Prostate Cancer | active not recruiting | Phase 2 | 110 | Mayo ClinicOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06205316 | SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma | active not recruiting | Phase 3 | 118 | Mayo ClinicOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT05053152 |
| Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study |
| active not recruiting |
| Phase 2 |
| 194 |
| NRG OncologyOTHER |
| 2 |
| Aug 17, 2026 |
| clinicaltrials |
| NCT04190446 | A Study To Evaluate Hypofractionated Proton Therapy Or IMRT For Recurrent, Oligometastatic Prostate Cancer | active not recruiting | Phase 2 | 84 | Mayo ClinicOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT05496959 | 177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, The LUNAR Study(LUNAR) | active not recruiting | Phase 2 | 93 | Jonsson Comprehensive Cancer CenterOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT06389786 | Accuracy of 18F-rhPSMA-7.3 PET/ MRI for Prediction of Lymph Node Metastasis in Localized High-Risk Prostate Cancer | recruiting | N/A | 50 | Mayo ClinicOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT06229366 | [Ac-225]-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer(ACCEL) | active not recruiting | Phase 1 | 142 | Eli Lilly and CompanyINDUSTRY | 1 | Dec 22, 2025 | clinicaltrials |
| NCT06674863 | Addressing Health Literacy With a Tailored Survivorship Care Plan | recruiting | N/A | 150 | Emory UniversityOTHER | 1 | Dec 9, 2025 | clinicaltrials |
| NCT06273345 | OLIGOS: Impact of Treatment on Primary Tumour in Patients With Newly Diagnosed Oligometastatic Neoplasia of the Prostate(OLIGOS) | recruiting | — | 150 | Istituto Oncologico Veneto IRCCSOTHER | 1 | Apr 17, 2025 | clinicaltrials |
| NCT05707468 | Neoadjuvant Radiohormonal Therapy for Oligometastatic Prostate Cancer | not yet recruiting | N/A | 200 | Changhai HospitalOTHER | 1 | Feb 20, 2024 | clinicaltrials |
Data updated 5 days agoSource updated Sep 25, 2026source: clinicaltrials